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Pesaro and Bologna, Italy; Ann Arbor, Michigan; Rostock, Germany; and Boston, MassachusettsObjectives This study sought to evaluate long-term survival in type B aortic dissection patients
treated with thoracic endovascular aortic repair (TEVAR) therapy.
Background Historical data have supported medical therapy in type B acute aortic dissection (TBAAD)
patients. Recent advances in TEVAR appear to improve in-hospital mortality.
Methods We examined 1,129 consecutive patients with TBAAD enrolled in IRAD (International
Registry of Acute Aortic Dissection) between 1995 and 2012 who received medical (n ¼ 853, 75.6%) or
TEVAR (n ¼ 276, 24.4%) therapy.
Results Clinical history was similar between groups. TEVAR patients were more likely to present with
a pulse deﬁcit (28.3% vs. 13.4%, p < 0.001) and lower extremity ischemia (16.8% vs. 3.6%, p < 0.001),
and to characterize their pain as the “worst pain ever” (27.5% vs. 15.7%, p < 0.001). TEVAR patients
were also most likely to present with complicated acute aortic dissection, deﬁned as shock, periaortic
hematoma, signs of malperfusion, stroke, spinal cord ischemia, mesenteric ischemia, and/or renal
failure (61.7% vs. 37.2%). In-hospital mortality was similar in patients managed with endovascular
repair (10.9 % vs. 8.7%, p ¼ 0.273) compared with medically managed patients. One-year mortality was
also similar in both groups (8.1% endovascular vs. 9.8% medical, p ¼ 0.604). Among adverse events
during follow-up, aortic growth/new aneurysm was most common, occurring in 73.3% of patients with
medical therapy and in 62.7% of patients after TEVAR, based on 5-year Kaplan-Meier estimates. Kaplan-
Meier survival estimates showed that patients undergoing TEVAR had a lower death rate (15.5% vs.
29.0%, p ¼ 0.018) at 5 years.
Conclusions Results from IRAD show that TEVAR is associated with lower mortality over a 5-year
period than medical therapy for TBAAD. Further randomized trials with long-term follow-up are
needed. (J Am Coll Cardiol Intv 2013;6:876–82) ª 2013 by the American College of Cardiology
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877Thoracic endovascular aortic repair (TEVAR) is an emerging
strategy in the treatment of descending aortic disease (1–4).
Initial studies demonstrated the technical feasibility and
relative safety of endovascular approaches, even in the difﬁcult
clinical scenario of complicated type B acute aortic dissectionTable 1. Demographic and Clinical Characteristics of Type B Dissection
Patients According to Management
Overall Medical TEVAR p Value
All patients with
type B dissection
1,150 (100) 860 (74.8) 290 (25.2)
Demographics
Age, yrs 65.2  13.9 62.2  13.4 0.002
Male 731 (64.7) 527 (61.8) 204 (73.9) <0.001
White 890 (82.4) 671 (82.1) 219 (83.3) 0.673
European centers 419 (37.1) 302 (35.4) 117 (42.4) 0.037
North American
centers
651 (57.7) 495 (58.0) 156 (56.5) 0.659
Patient’s history
Hypertension 895 (81.1) 673 (80.2) 222 (84.1) 0.160
Marfan syndrome 30 (2.7) 21 (2.5) 9 (3.4) 0.435
Bicuspid aortic valve 16 (1.7) 14 (2.0) 2 (0.8) 0.260
Atherosclerosis 349 (32.0) 288 (34.9) 61 (23.1) <0.001
Prior cardiac surgery 193 (18.3) 151 (18.9) 42 (16.2) 0.327
Presenting hemodynamics
Hypertension 729 (69.2) 552 (68.1) 177 (73.1) 0.133
Hypotension 26 (2.5) 21 (2.6) 5 (2.1) 0.645
Shock 10 (0.9) 8 (1.0) 2 (0.8) 1.000
Hypotension/shock 36 (3.4) 29 (3.6) 7 (2.9) 0.608
Pain severity
Mild 59 (6.2) 53 (7.4) 6 (2.6) 0.010
Severe 715 (75.3) 555 (77.0) 160 (69.9) 0.030
Worst ever 176 (18.5) 113 (15.7) 63 (27.5) <0.001




21 (2.0) 14 (1.7) 7 (2.9) 0.292
Mesenteric ischemia/
infarction
48 (4.6) 20 (2.5) 28 (10.9) <0.001
Acute renal failure 153 (14.6) 98 (12.4) 55 (21.4) <0.001
Limb ischemia 94 (8.5) 40 (4.8) 54 (20.6) <0.001
Ischemic lower
extremity
70 (6.6) 29 (3.6) 41 (16.8) <0.001
Any pulse deﬁcit 149 (16.9) 91 (13.4) 58 (28.3) <0.001
Leg pain on
presentation
120 (11.6) 66 (8.4) 54 (21.7) <0.001
Any of the above
signs of malperfusion
369 (33.3) 236 (28.0) 133 (50.4) <0.001
Imaging ﬁndings
Periaortic hematoma 136 (13.9) 98 (13.1) 38 (16.7) 0.164
Pleural effusion at
chest x-ray
134 (15.6) 100 (15.0) 34 (17.4) 0.412
Complicated dissection* 478 (43.1) 315 (37.2) 163 (61.7) <0.001
Values are n (%) or mean  SD. *Complications include shock, periaortic hematoma, signs of
malperfusion, stroke, spinal cord ischemia, mesenteric ischemia, and/or renal failure.
TEVAR ¼ thoracic endovascular aortic repair.(TBAAD) (5–12). However, survival data are limited by
small case series or short follow-up periods. Furthermore,
a randomized study of descending aortic dissection in the
subacute phase failed to demonstrate any survival beneﬁt to
TEVAR compared with medical therapy at 2 years after
treatment (13). We utilized the resources of IRAD (the
International Registry of Acute Aortic Dissection) to analyze
the long-term outcomes of patients with TBAAD treated
with an endovascular technique compared with those under-
going medical management alone.
Methods
IRAD is a multinational registry of 24 referral centers in 12
countries, designed to provide an unbiased representative
population of patients with acute aortic dissection. Full
details of the IRAD methods and registry structure have
been previously described (14–19). Data were obtained from
hospital records of 3,865 patients enrolled in IRAD with
acute aortic dissection between December 26, 1995, and
January 20, 2012, 1,333 of whom were classiﬁed as
TBAAD. A full list of IRAD contributors is provided in the
Online Appendix.Abbreviations
and Acronyms
IQR = interquartile range
TBAAD = type B acute aortic
dissection
TEVAR = thoracic
endovascular aortic repairStudy population. In IRAD,
patients were identiﬁed prospec-
tively at the time of presentation
or retrospectively from discharge
diagnosis, and from imaging and
surgical databases. The study
population consisted of 1,129
patients with TBAAD enrolled
in IRAD between December 26, 1995, and January 20,
2012, who underwent either medical therapy (n ¼ 853,
74.8%) or endovascular stent-graft placement (n ¼ 276,
25.2%) in addition to medical therapy (Table 1). Speciﬁcs
regarding endovascular technique were available in 138
patients, some of whom had multiple stents, and consisted of
stent-graft placement in the descending aorta (n¼ 100) and/
or in the abdominal aorta (n ¼ 48) using a commercially
available stent graft with or without percutaneous fenestration
(n ¼ 39) or peripheral vessel stenting (n ¼ 39), according to
standardmethods (Table 2). Patients withTBAAD subjected
to open surgical repair during the acute phase (183, 13.6%)
were not considered in this analysis. Diagnosis was based on
conﬁrmatory imaging at each center. A total of 1,025 patients
were discharged alive, and 580 (56.6%) had consecutive
follow-up data available. When looking at variables from the
initial hospitalization, patients with follow-up data available
were more likely to be male, have an abnormal chest x-ray
without associated pain, and were more likely to have angio-
tensin-converting enzyme inhibitors prescribed at discharge.
Additionally, these patients had signiﬁcantly more in-hospital
stroke, larger descending aortic diameters, and longer length of
stay. Conversely, patients whowere lost to follow-upweremore
Table 2. Endovascular Procedure
Overall Survived Died p Value
Stent graft only
(no fenestration)
237 (85.9) 211 (85.8) 26 (86.7) 1.000
Descending thoracic stent
graft
110 (72.8) 95 (71.4) 15 (83.3) 0.401
Thoracoabdominal stent
graft
26 (19.4) 24 (20.3) 2 (12.5) 0.737
Infrarenal stent graft 22 (16.2) 19 (15.8) 3 (18.8) 0.724
Fenestration þ stent graft 39 (14.1) 35 (14.2) 4 (13.3) 1.000
Stenting þ any type of
peripheral stenting
(of the 3 below)
39 (30.2) 34 (29.6) 5 (35.7) 0.759
Celiac artery stenting 2 (1.5) 2 (1.7) 0 (0.0) 1.000
Superior mesenteric artery
stenting
15 (11.4) 12 (10.2) 3 (21.4) 0.199
Renal artery stenting 28 (20.9) 25 (21.2) 3 (18.8) 1.000
Values are n (%).
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878likely to have a history of percutaneous coronary intervention
and to present with anterior chest pain. No other differences
among in-hospital variables were seen between patients who
had follow-up data reported and those who did not. In patients
who had follow-up, their respective follow-up periods were
deﬁned as the portion of time for which each patient had
consecutive data available starting 1 year from the incident
event.
Data collection. Data were collected on standardized forms
with standard IRAD deﬁnitions. Information on 290 clinical
variables was collected, including patient demographics,Figure 1. Maximum Diameter of the Descending Aorta
The diameter of the aortas of patients treated with thoracic endovascular aortic repa
points: in-hospital and at 1 and 5 years post-discharge.medical history, clinical presentation, physical ﬁndings,
imaging studies, details of medical and endovascular
management, in-hospital clinical events, length of stay, and
in-hospital mortality. Yearly follow-up data were obtained up
to 5 years after discharge with standardized forms. Data
forms were entered into an online database maintained by
the IRAD coordinating center at the University of Michigan.
Statistical analysis. Data are shown as frequencies and
percentages and as mean  SD. Missing data were not
defaulted to negative, and denominators reﬂect only re-
ported cases. Associations of death among nominal variables
were compared using the chi-square test or Fisher exact test
when appropriate, and among continuous variables, using
the Student t test. Kaplan-Meier analysis was used for
follow-up data. Only patients with consecutive follow-up,
beginning at 1 year, were included in the analysis.
Because patients were not randomly assigned to the 2
treatment groups, a propensity model utilizing a multivari-
able binary logistic regression was developed to generate
a propensity score from the conditional probability computed
for endovascular treatment versus medical treatment. The
Hosmer-Lemeshow test p value was 0.261, with a c-statistic
of 0.725. A propensity-matched dataset was then created,
matching the propensity score for patients undergoing
endovascular treatment with the propensity score for patients
undergoing medical treatment only. A 2:1 matching scheme
was utilized for the control group (medical management
only) versus the treatment group (endovascular procedure).
Chi-square or Fischer exact tests were performed to evaluate
differences between the 2 groups regarding in-hospital andir are compared with those of patients managed medically at the following time
Table 3. In-Hospital Outcomes
Overall Medical TEVAR p Value
In-hospital mortality 104 (9.2) 74 (8.7) 30 (10.9) 0.273
Complications
Cerebrovascular accident 15 (1.4) 9 (1.1) 6 (2.3) 0.217
Coma 5 (0.5) 4 (0.6) 1 (0.4) 1.000
Spinal cord ischemia 10 (1.0) 7 (1.0) 3 (1.3) 0.712
Acute renal failure 164 (15.6) 99 (12.5) 65 (25.3) <0.001
Extension of dissection 72 (6.9) 46 (5.8) 26 (10.2) 0.016
Died while awaiting surgery 3 (1.7) 3 (2.8) 0 (0.0) 0.275
Values are n (%).
TEVAR ¼ thoracic endovascular aortic repair.
Table 4. Clinical/Imaging Features at 1 Year of Patients With
Follow-Up Available
Overall Medical Endovascular p Value
Adverse events
1-yr follow-up mortality 43 (9.4) 35 (9.8) 8 (8.1) 0.604
Recurrence of symptoms
(þ pain related to dissection)
96 (23.8) 72 (23.5) 24 (25.0) 0.756
Re-hospitalization 59 (14.5) 43 (13.7) 16 (17.0) 0.421
Late intervention 41 (20.8) 28 (20.6) 13 (21.3) 0.771
Extension of dissection
(or new dissection)




103 (28.3) 77 (27.5) 26 (31.0) 0.538
Widest diameter of the
descending aorta, cm
4.2 (3.5–5.0) 4.0 (3.5–4.9) 0.416
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879follow-up outcomes, which were similar between manage-
ment types for all variables considered.Stent graft migration 1 (1.6) N/A 1 (2.0) d
Stent graft endoleak 6 (9.2) N/A 6 (11.5) d
Values are n (%) or median (interquartile range).
Figure 2. Kaplan-Meier Survival Estimates
Patients with type B dissection subjected to thoracic endovascular aortic
repair are compared with those treated with medical therapy alone.Results
Clinical characteristics at presentation and in-hospital out-
come. Among patients in IRAD with TBAAD (1,129
patients), 853 (74.8%) patients were initially treated medically,
and 276 (25.2%) were managed using an endovascular
approach. There were several signiﬁcant differences in the
demographic statistics between the 2 groups (Table 1).
Endovascular stent-graft therapy was more frequently used in
European centers as compared with North American sites,
and was used preferentially in males and patients with non-
atheromatous aortic disease. Patients receiving endovascular
treatment were more likely to present with clinical signs of
malperfusion, such as leg pain (21.7% vs. 8.4%, p < 0.001)
and limb ischemia (20.6% vs. 4.8%, p < 0.001). TEVAR
patients were also more likely to have characterized their pain
as the “worst pain ever” (27.5% vs. 15.7%, p < 0.001). Pre-
operative acute renal failure (21.4% vs. 12.4%, p < 0.001)
and any pulse deﬁcit on presentation (28.3% vs. 13.4%,
p < 0.001) were particularly prevalent in the interventional
group. Finally, patients with endovascular management were
more likely to have complicated dissections, deﬁned by the
presence of shock, periaortic hematoma, signs of malperfu-
sion, stroke, spinal cord ischemia, mesenteric ischemia/
infarction, and/or acute renal failure (61.7% vs. 37.2%,
p < 0.001). No signiﬁcant difference in the median baseline
maximum descending aortic diameter was demonstrated
between groups (4.0 [interquartile range (IQR): 3.3 to 4.7]
endovascular vs. 4.0 [IQR: 3.5 to 4.8] medical, p ¼ 0.590)
(Fig. 1).
In-hospital mortality was similar in patients subjected to
endovascular repair (10.9% vs. 8.7%, p ¼ 0.273), as
compared with those under medical treatment alone
(Table 3). Post-procedure, only 2 endovascular patients
(0.8%) developed spinal cord ischemia who did not have the
condition on presentation. Complications during the acute
phase (renal failure, cerebrovascular accidents, spinal cordischemia, extension of dissection) occurred in 204 patients
(22.7%) and were more common in patients submitted to
TEVAR compared with patients given medication alone
(38.9% vs. 17.8%).
One-year follow-up. Five hundred eighty patients were dis-
charged alive with documented clinical follow-up data.
Mortality at 1-year post-discharge was 8.1% in patients
previously treated with endovascular stent grafts and 9.8%




(Cumulative %) p Value
Freedom from recurrence of
symptoms or new symptoms
1 yr 75.6 (260) 73.3 (70) 0.970
2 yrs 68.2 (132) 73.3 (36)
3 yrs 65.4 (71) 70.2 (23)
4 yrs 62.5 (45) 64.8 (12)
5 yrs 60.6 (32) 64.8 (5)
Freedom from rehospitalization
1 yr 85.6 (267) 81.6 (76) 0.699
2 yrs 83.3 (148) 81.6 (42)
3 yrs 82.4 (88) 81.6 (27)
4 yrs 82.4 (63) 81.6 (15)
5 yrs 80.3 (39) 81.6 (8)
Freedom from late intervention
1 yr 82.2 (135) 79.6 (51) 0.479
2 yrs 81.5 (128) 77.1 (31)
3 yrs 80.3 (127) 77.1 (18)
4 yrs 80.3 (126) 69.4 (9)
5 yrs 80.3 (125) 69.4 (4)
Freedom from new dissection
or redissection
1 yr 89.3 (259) 87.8 (72) 0.888
2 yrs 87.4 (143) 87.8 (40)
3 yrs 85.4 (86) 87.8 (26)
4 yrs 84.1 (63) 87.8 (13)
5 yrs 84.1 (40) 87.8 (7)
Freedom from aortic growth
or new aneurysm
1 yr 86.6 (254) 81.5 (73) 0.822
2 yrs 74.9 (155) 72.5 (44)
3 yrs 65.5 (95) 60.0 (28)
4 yrs 53.4 (69) 56.0 (14)
5 yrs 26.7 (45) 37.3 (8)
Endovascular patients only
Freedom from stent graft migration
1 yr d 98.1 (52) -
2 yrs d 98.1 (32)
3 yrs d 93.4 (20)
4 yrs d 93.4 (11)
5 yrs d 93.4 (6)
Freedom from stent graft endoleak
1 yr d 93.5 (52) -
2 yrs d 90.8 (33)
3 yrs d 86.6 (21)
4 yrs d 86.6 (12)
5 yrs d 86.6 (7)
Values are % (n at risk).
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880for patients with medical therapy alone (Table 4), and
adverse events were similar in both groups. Speciﬁcally,
recurrence of any symptoms or pain was described in 96
patients (72, or 23.5%, with medical therapy, and 24, or
25.0%, with TEVAR, p ¼ 0.756), whereas a new inter-
vention, deﬁned as a change in therapy or additional stent-
graft placement during follow-up, was necessary in 46
patients (21.4% of endovascular patients vs. 19.7% of
medically managed patients, p ¼ 0.771). Extension of
dissection or new dissection occurred in 37 patients (10.2%):
30 (10.7%) with medical therapy and 7 (8.4%) after stent
graft (p ¼ 0.546). Again at 1 year, no signiﬁcant difference
was observed in the median diameter of the descending aorta
at imaging follow-up (median, 4.2 [IQR: 3.5 to 5.0] cm
medical therapy vs. median 4.0 [IQR: 3.5 to 4.9] cm
TEVAR, p ¼ 0.416) (Fig. 1).
Long-term follow-up. Kaplan-Meier survival estimates at 5
years showed that patients subjected to endovascular treat-
ment had a lower death rate (15.5% vs. 29.0%, p ¼ 0.018)
(Fig. 2). Five-year estimates for late intervention were 30.6%
after TEVAR versus 19.7% in medically managed patients
(p¼ 0.810). Low incidence of stent-graftmigration (6.6%) and
endoleak (13.4%) was observed after initial TEVAR (Table 5).
Extension of dissection or new dissections were identiﬁed in
12.2% of TEVAR patients versus 15.9% with medical
management (p ¼ 0.888) (Fig. 3). Interestingly, although no
signiﬁcant difference in diameter of the descending aorta was
present at 1 year in both groups, at 5 years, the diameter of the
descending aorta was signiﬁcantly smaller after stent graft as
compared with medical therapy alone (median, 4.6 [IQR: 3.6
to 5.5] cmmedical therapy vs.median, 4.2 [IQR: 3.8 to 5.2] cm
TEVAR, p ¼ 0.034) (Fig. 1).
Discussion
The appropriate treatment strategy for descending aortic
dissection has long been a matter of debate. For many years,
there was a consensus that patients with type B dissections
should be medically treated unless life-threatening compli-
cations occurred. However, the long-term prognosis of
untreated chronic type B dissection is sobering, with survival
estimates at 5 years ranging from just 60% to 80% (20–27).
Once the aortic diameter exceeds 60 mm, the risk of rupture
is estimated at 30% per annum (20). Furthermore, although
medical therapy may delay expansion of the descending
aorta, it fails to enhance the remodeling process. Subsequent
elective late aortic interventions are required in 25% to 30%
of patients for aneurysm expansion, extension of the
progressive dissection, and other related complications
arising from the unresolved dissection process (21,22).
Studies suggest that endovascular techniques may shift the
risk of patients with acute complicated type B dissection
from high to lower mortality (18), comparable to that seen in
uncomplicated distal dissection. In the setting of acutecomplicated type B dissection, the IRAD database suggests
a better outcome in patients treated with stent graft
compared with open surgical repair, lowering short-term
mortality to the level of medically managed uncomplicated
Figure 3. Kaplan-Meier Estimates of Freedom From New Dissection
or Extension of Dissection
Patients with type B dissection subjected to thoracic endovascular aortic
repair are compared with those treated with medical therapy alone.
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881type B dissection (18). The present analysis at 5 years seems
to corroborate a long-term beneﬁt of endovascular repair
over medical management alone, despite an initially higher
risk category of TEVAR patients, demonstrated by the
41.5% of cases who were considered complicated at admis-
sion. The 5-year Kaplan-Meier mortality estimates were
signiﬁcantly lower for patients managed with interventional
techniques (15.5% TEVAR vs. 29.0% medical), despite the
initially higher risk proﬁle due to the complicated nature of
the dissection patients subjected to TEVAR.
The IRAD database analysis, which reﬂects the “real-
world“ scenario, supports the premise of long-term advan-
tages in survival with selected endovascular treatment as
compared with open surgical strategies and/or medical
management alone. It is important to emphasize also that
extension of dissection observed in follow-up may not be
a complication of stent-graft treatment, but rather the
progressive nature of the aortic disease continuum (28,29).
Study limitations. Several considerations are important in
interpreting the results of this study. The IRAD cohort
includes patients referred to and treated at centers special-
izing in aortic disease; therefore, the results may not reﬂect
management of patients treated at community hospitals.
Patients were not randomized to a predetermined treatment
strategy, but subjected to contemporary best therapy at eachcenter; therefore, results could be partially related to selec-
tion bias. Most importantly, as with all retrospective
observational studies, the database is subject to referral bias,
and information on complications and cause of death may
potentially reﬂect slightly different data interpretation.
Conclusions
Historical data have supported the use of medical therapy in
patients who survived an acute type B aortic dissection. In
IRAD, a subgroup of acute type B dissection patients treated
with endovascular repair showed better 5-year survival
compared with patients with medical therapy alone. If long-
term follow-up and randomized studies support these
preliminary data, it appears that uncomplicated type B aortic
dissection could become an indication for early elective
endovascular stent grafting.Reprint requests and correspondence: Prof. Rossella Fattori,
International Cardiology Unit, San Salvatore Hospital, Piazzale
Cinelli 4, 61121 Pesaro, Italy. E-mail: rossella.fattori@unibo.it.REFERENCES
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